Roche Expects Blockbuster Cancer Pill Launch by Year End

Roche Holding AG expects to launch the breast cancer pill that may become one of its biggest sellers by the end of the year, sparking optimism about its prospects.

The medicine, called giredestrant, will likely win regulatory approval in the US in the last months of the year, Chief Executive Officer Thomas Schinecker said in a Bloomberg television interview.